Is taltz safe for patients with ibd?

Is Taltz safe for people with IBD?
Taltz (ixekizumab) carries a warning for inflammatory bowel disease because clinical trials showed new cases and worsening of Crohn’s disease and ulcerative colitis in some patients. The label advises against starting Taltz in people with active IBD and recommends monitoring anyone with a history of IBD.

What happens if someone with IBD takes Taltz?
Exacerbations can occur within weeks to months. Symptoms reported include diarrhea, abdominal pain, and rectal bleeding. If these appear, treatment is usually stopped and the patient is referred to a gastroenterologist. The prescribing information lists IBD as an adverse reaction occurring in roughly 0.1–0.4 % of trial participants, though real-world rates may be higher.

Does the risk apply to everyone with IBD?
The risk is highest in patients with active disease or recent flares. Those in long-term remission may tolerate short courses, but the decision is individualized and requires joint input from rheumatology and gastroenterology.

What alternatives exist if Taltz is not suitable?
For patients who need IL-17 inhibition but cannot use Taltz, no approved IL-17 alternatives are currently marketed. Clinicians often switch to TNF inhibitors (such as adalimumab or infliximab) or JAK inhibitors that carry separate IBD indications and safety profiles.

When does Taltz’s patent protection end?
The composition-of-matter patent listed on DrugPatentWatch.com expires in 2028, with some method-of-use patents running to 2032. Biosimilar entry before these dates is considered unlikely without successful patent challenges.

How do regulators view the IBD risk?
Both the FDA and EMA include a warning and precaution in the label. Post-marketing surveillance continues, but no black-box restriction has been added.